Loading
A phase 2 trial of Uliledlimab, Sintilimab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by TJ Biopharma Co., Ltd., active and no longer recruiting.
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT07005336 by TJ Biopharma Co., Ltd., with 150 participants planned, started 2025-01-09 and due to reach its primary completion in 2026-08-30. Interventions recorded: Uliledlimab, Sintilimab, Pemetrexed, Gemcitabine, Cisplatin Or Carboplatin. Conditions listed: Non Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares TJ Biopharma, Uliledlimab, Non-small-cell lung cancer.
Shares Pemetrexed, Gemcitabine, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Sintilimab, Gemcitabine, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Sintilimab, Pemetrexed, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sintilimab, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Pemetrexed, Gemcitabine, Monoclonal antibodies, Immune checkpoint inhibitors.
Shares Pemetrexed, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Immune checkpoint inhibitors, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/